Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monsenso ASOCSE:MONSO -18.03%29 EPS without NRI is kr-0.11 as of Dec. 2025. GuruFocus rates OCSE:MONSO with a GF Score™ of 29/100 and a GF Value™ of kr0.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 512 Healthcare Providers & Services companies, Monsenso AS ranks better than 71.87% on this metric.
Monsenso AS's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was kr-0.05.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.11.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 28.80% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 28.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Monsenso AS's EPS without NRI or its related term are showing as below:
OCSE:MONSO'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -144 Med: 23.3 Max: 40.5
Current: 28.8
During the past 9 years, Monsenso AS's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 40.50% per year. The lowest was -144.00% per year. And the median was 23.30% per year.
OCSE:MONSO's 3-Year EPS without NRI Growth Rate is ranked better than 71.87% of 512
companies
in the Healthcare Providers & Services industry
Industry Median: 11.65
vs OCSE:MONSO: 28.80
Monsenso AS's EPS (Diluted) for the
six
months ended in Dec. 2025 was kr-0.05.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.11.
Monsenso AS's EPS (Basic) for the
six
months ended in Dec. 2025 was kr-0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.11.
Monsenso AS (OCSE:MONSO) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Monsenso AS EPS without NRI Related Terms
Monsenso AS EPS without NRI Historical Data
* Premium members only.
The historical data trend for Monsenso AS's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:MONSO vs VEEV, BTSG, TEM: EPS without NRI Comparison
For the Health Information Services subindustry, Monsenso AS's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monsenso AS PE Ratio without NRI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Monsenso AS's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Monsenso AS's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monsenso AS (OCSE:MONSO) has a EPS without NRI of kr-0.11 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Monsenso AS and its competitors. According to the industry distribution chart, Monsenso AS ranks #144 out of 512 companies in the Healthcare Providers & Services industry, placing it in the top 28.1%.
Is Monsenso AS's EPS without NRI too high?
Monsenso AS's current EPS without NRI is kr-0.11. Based on the distribution chart, Monsenso AS ranks #144 out of 512 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Monsenso AS has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monsenso AS's EPS without NRI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Monsenso AS ranks #144 out of 512 companies for EPS without NRI. This puts Monsenso AS in the upper half of its industry. The industry median EPS without NRI is 11.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.65, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Monsenso AS and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monsenso AS's current EPS without NRI is kr-0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monsenso AS stock overvalued right now?
Based on GuruFocus' analysis, Monsenso AS (OCSE:MONSO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.30 — trading 100% above its estimated fair value. The current EPS without NRI is kr-0.11. Monsenso AS's overall GF Score™ is 29/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Monsenso AS (OCSE:MONSO), the current EPS without NRI is kr-0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monsenso AS (OCSE:MONSO) Overvalued in 2026?
Based on GuruFocus' analysis, Monsenso AS stock appears to be overvalued.
The current stock price of kr0.30 is trading 100% above its estimated GF Value™ of kr0.15.
GuruFocus considers Monsenso AS to be Significantly Overvalued.
Key valuation signals for OCSE:MONSO:
EPS without NRI: kr-0.11
GF Value™: kr0.15 vs. price of kr0.30 (100% above fair value)
No single metric tells the full story. See the OCSE:MONSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monsenso AS is a mobile mental health company. It technology company offering a digital health solution used for decentralized trials, remote patient monitoring, and treatment support. The company's mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data, and the solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence, and behavioral data.
29GF Score
Get the complete analysis for OCSE:MONSO
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:MONSO has been successfully added to your 
